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resources speciﬁcally allocated to health technologies is the Health
Care Formulary and Supply Catalog (Cuadro Básico y Catálogo de
Insumos del Sector Salud [CBCISS]). The aim of the CBCISS is to
collaborate in the optimization of public resources through the use of
technologies (supplies) that have proven their safety, therapeutic
efﬁcacy, and efﬁciency. The importance of the CBCISS lies in the fact
that all public institutions within the National Health System must
use only the established technologies it contains. The implementation
of strategies that strengthen the CBCISS update process allows it to be
thought of as an essential regulatory tool for the introduction of
health technologies, with relevant contributions to the proper selec-
tion of cost-effective interventions. It ensures that each supply
included on the list meets the criteria sufﬁcient and necessary to
ensure efﬁcacy, safety, effectiveness, and, of course, efﬁciency, as
evidence supporting the selection of suitable technologies. The Gen-
eral Health Council (Consejo de Salubridad General [CSG]) is a collegial
body of constitutional origin that—in accordance with its authority—
prepares, updates, publishes, and distributes the CBCISS. To perform
these activities, the CSG has the CBCISS Inter-institutional Commis-
sion. The CBCISS update is performed through the processes ofee front matter Copyright & 2014, International S
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mpliación Miguel Hidalgo, Delegación Tlalpan, C.Pinclusion, modiﬁcation, and exclusion of supplies approved by the
Interior Commission. The CBCISS update process consists of three
stages: the ﬁrst stage involves a test that leads to the acceptance or
inadmissibility of the requests, and the other two focus on an in-
depth evaluation for the ruling. This article describes the experience
of health technology assessment in Mexico, presents the achieve-
ments and outlines the improvements in the process of submission of
new health technologies, and presents a preliminary analysis of the
submissions evaluated until December 2012. During the analysis
period, 394 submissions were received. After conﬁrming compliance
with the requirements, 59.9% of the submissions passed to the next
stage of the process, technology assessment. In the third stage, the
committee approved 44.9% of the submissions evaluated. The
improvements established in the country in terms of health technol-
ogy assessment allowed choosing the technologies that give more
value for money in a context of public health institutions.
Keywords: efﬁciency, health care, health technologies, health
technology assessment.
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The search for equity, quality of care, and efﬁciency has been one
of the challenges facing public health systems (PHSs) worldwide.
In that context, health technology assessment plays a signiﬁcant
role in gaining greater beneﬁts for the health care ﬁeld and
planning of the rational use of resources.
As a result, recent decades have been characterized by
signiﬁcant progress in the supply and availability of new health
technologies (HTs). Many of these technologies have budgetary
implications owing to the high costs of their incorporation.
Despite the beneﬁts offered by these new technologies as com-
pared with existing ones, their incorporation does not always
solve the population’s major health issues and they are not
effectively accessed by all public sector institutions.One of the instruments Mexico has available for the optimi-
zation of resources for HTs is the Health Care Formulary and
Supply Catalog (Cuadro Básico y Catálogo de Insumos del Sector
Salud [CBCISS]) [1], and as such, the strategies developed to
strengthen it must be favorable in terms of meeting the growing
demands for technology and health care services in a difﬁcult
economic and social environment.The Health Care Formulary and Supply Catalog
The CBCISS is a document that includes, deﬁnes, and encodes all
medical supplies used by public institutions to provide health
services to the population.ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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peia [2] was published, and its development over time has set the
standards for PHSs. In 1975, a presidential decree [3] was
published that established that all public health institutions must
have a drug formulary (Cuadro Básico de Medicamentos [CBM]).
That same year, the Public Sector Drug Formulary Commission
was formed, responsible for the development of the ﬁrst sectoral-
type CBM in 1977 [4]. Later, in 1983, biological products and
laboratory reagents, instruments and medical equipment, wound
dressing materials, and prosthetics were added to the CBM [5].
In 1996, for the purpose of facilitating information about the
supplies used in the support of diagnosis and treatment, the CBM
was divided into two parts, on the basis of the type of medical
unit: one referred to as formulary for primary care and the other
called catalog for secondary and tertiary care [6], just as we know
it today.
The aim of the CBCISS is to ensure the optimization of public
resources through the use of technologies (supplies) that have
proven their safety, therapeutic efﬁcacy, and efﬁciency. The
importance of the CBCISS lies in the fact that all public institu-
tions within the National Health System must use only the
established technologies it contains.
To reinforce its compulsory nature, the bylaws of the CBCISS
Inter-institutional Commission were published in the Ofﬁcial
Gazette of the federation in February 2003, which specify the
powers of the Inter-institutional Commission and Speciﬁc Tech-
nical Committees (Comité Técnico Especíﬁco [CTEs]) as well as
institutional representatives. In addition, it describes the CBCISS
update procedure [7].Strategies for Strengthening the Update Process
We know that as a country becomes more developed, the burden
and weight of disease increase, especially for noncommunicable
diseases that accompany the epidemiological transition. This
translates into new health care needs and causes the develop-
ment of new technologies that revolutionize medical practice and
contribute to the challenge facing the PHSs, which is to improve
the quality of care and supplies, making them safe, effective,
efﬁcacious, and efﬁcient services and supplies.
Against this backdrop, the CBCISS Inter-institutional Com-
mission of the General Health Council, through the Directorate
for Prioritization, was given the task of strengthening the CBCISS
update process, implementing strategies that contribute to the
effective and efﬁcient use of technology in PHSs.
Some of these strategies were as follows: The organization of a structure dedicated to the assessment
and evaluation of the information contained in the requests,
primarily those that include HTs. The amendment and approval of the bylaws of the CBCISS
Inter-institutional Commission, published in the Ofﬁcial Gaz-
ette in June 2011 [8], to have a legal regulatory framework that
supports the process. The bylaws contain seven sections,
which provide for the activities and responsibilities of the
commission, the requirements that CBCISS update requests
must meet, and the timing thereof. The development of the Guidelines for the Evaluation of
Supplies (Guía de Evaluación de Insumos [GEI]) [9] with the
application of standardized criteria based on scientiﬁc meth-
ods to evaluate the clinical, epidemiological, and economic
evidence from the studies presented in the update proposals
and the process to obtain a ruling.
The strategy consists of three key, interconnected themes for
the update process: transparency, scientiﬁc evidence, andefﬁciency. On the one hand, these strategies help to overcome
the inefﬁcient use of limited resources, as one of the main
obstacles identiﬁed in the health world, and on the other hand,
they align the efforts of the institutions and stakeholders
involved in the process, avoiding the duplication of effort in the
initial evaluation.
The General Health Council (Consejo de Salubridad General
[CSG]) is a collegial body of constitutional origin that—in
accordance with its authority—prepares, updates, publishes,
and distributes the Formulary for the primary health care level
and the Supply Catalog for the secondary and tertiary levels. To
perform these activities, the CSG has the CBCISS Inter-
institutional Commission, which is composed of representatives
of the Ministry of Health, the Mexican Social Security Institute,
the Government Employees’ Social Security and Services Insti-
tute, the National System for Integral Family Development, the
Ministry of National Defense, the Secretariat of the Navy,
Petróleos Mexicanos, and the Federal District’s Ministry of
Health.
For the purposes of updating the CBCISS, the commission has
a Technical Secretariat under the Directorate-General for Priori-
tization and Speciﬁc Technical Committees (CTE) for medicines,
wound dressing materials, diagnostic aids, and instruments and
medical equipment, in addition to the Technical Committees for
herbal remedies, homeopathic medicines, and acupuncture sup-
plies, which were recently formed as part of the strategy to
strengthen the upgrade process. Each CTE consists of represen-
tatives of the commission’s full members and is coordinated by
its technical secretary.Update Process
The CBCISS update is performed through the processes of
inclusion, modiﬁcation, and exclusion of supplies approved by
the Interior Commission.
Update requests are received at the CSG during the ﬁrst ﬁve
working days of each period (January–April, May–August, Sep-
tember–December), in accordance with the bylaws, and they are
passed to the Directorate General for Prioritization, which, in
turn, acts as the Technical Secretariat of the Commission to
initiate the review and assessment process.
According to what was instituted by the new bylaws, CBCISS
update requests related to supplies may be made by public
institutions that serve as health care providers; scientiﬁc organ-
izations; academies and specialty boards; government institu-
tions; members of the commission; the secretary and the
chairman of the General Health Council; and providers or man-
ufactures of technology, who, to date, make the majority of
requests.Stages of the Upgrade Process
The CBCISS update process consists of three stages. The ﬁrst
stage involves a checklist that leads to the acceptance or
inadmissibility of the requests, and the other two focus on an
in-depth evaluation for the ruling.
The ﬁrst stage, called review and assessment of update
requests, leads to veriﬁcation of compliance by the Technical
Secretariat with the requirements instituted in the bylaws
(explicitly expressed, for the most part, in Article 28), to ensure
integrity, internal consistency, and accuracy: Request indicating generic name, code, and reasons for the
update request; Current Health Registration issued by the a decentralized
organ of the Department of Health with technical,
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to protect the population against sanitary risks, through
sanitary regulation Federal Commission for the Protection
against Sanitary Risk (Comisión Federal para la Protección
contra Riesgos Sanitarios, [COFEPRIS]), certiﬁed by a public
notary, except for supplies that do not require it, as deﬁned by
COFEPRIS; Declaration that the manufacturer has a technovigilance or
pharmacovigilance system and immediate notiﬁcation in
accordance with ofﬁcial regulations of the country (NOM-
220-SSA1-2004) [10]; Complete economic evaluation (EE) study as deﬁned in the
Guidelines for Conducting Economic Evaluation Studies for
the Update of the Health Care Formulary (Guía para la
conducción de estudios de evaluación económica para la
actualización del Cuadro Básico de Insumos del Sector Salud
en México [GCEEE]); Scientiﬁc studies that support the beneﬁts of the proposed
technology over other existing technologies with the same
indications in the CBCISS and/or Clinical Practice Guidelines,
as well as the values used to populate the economic models; Document with the generic proposal for the technology
requested for inclusion, in the correct format; A sworn statement that the supply item does not infringe on
patents nor is it under dispute and that the information is
accurate; Budget impact analysis for cases of low-incidence diseases
with social consequences (Article 29).
When it is determined that a request meets the requirements,
the applicant is notiﬁed in writing of the decision to continue the
process, and the approved requests, the accompanying docu-
mentation, and the review and assessment form for the requests
are sent to the appropriate committee.
In the second stage, known as assessment of the evidence, the
CTEs and the secretariat begin to get involved. In this stage, a
critical analysis of the clinical epidemiological studies is per-
formed, using instruments and forms developed by organizations
specializing in the topic (as established in the GEI), to evaluate
the methodological aspects that determine the internal and
external validity, as well as the risks and beneﬁts associated
with its use for health care in the target population, with the
corresponding direct impact on public resources.
With respect to the critical reading of EE studies, the following
aspects are considered: Is this economic evaluation valid? How
are costs evaluated and compared with the effects or consequen-
ces? Will the results help optimize the use of public resources
available for the funding of health interventions? These ques-
tions allow the analysis to focus considerably on the robustness
of the structure of the economic models and their uncertainty,
the plausibility of the data used to feed into the models, the
probability of making erroneous decisions and their consequen-
ces, and the applicability of the results to the target population.
The EE allows for a comparison of supplies, in terms of not
only the costs they generate but also the health effects they
produce. In this sense, the use of EE evidence seeks to improve
efﬁciency in the allocation of limited resources, systematically
selecting the safest, most effective, and least expensive option
among alternatives that compete for the same resources. This
evidence, however, presents limitations in terms of fully evalu-
ating the allocation of resources and may be seriously affected by
the models used or the necessary assumptions made when
building them. When the time comes to take decisions, the
members of the committee must be aware of these limitations
and the uncertainty associated with results of this type of
evaluation.The EE study as a requirement for updating the CBCISS was
established by the Inter-institutional Commission in May 2003,
prompting the development and publication of the Guidelines for
Conducting Economic Evaluation Studies for the Update of the
Health Care Formulary (GCEEE) in 2008 [11]. Since then, these
guidelines have made it possible to carry out a methodological
review consistent with standardized criteria from an economic
perspective.
For the third stage of the ruling, the CTEs convene on a regular
basis (monthly), seeking consensus to issue a unanimous deci-
sion, considering the opinions and recommendations of each
institution’s evaluator and, where appropriate, expert opinions.
Essentially, the conclusions and recommendations are backed by
prior review and analysis of the quality of clinical and economic
evidence; the balance between the risks, beneﬁts, and costs that
the new technology represents in comparison to existing alter-
natives; the scientiﬁc basis of the Clinical Practice Guidelines in
Mexico and/or other countries where its use is recommended; the
consideration of institutional resources available for the inter-
vention; and any other situations relevant to the social and
ethical context.
If any of the requests do not meet the established criteria, the
technology will not be considered for the CBCISS update. Through
its CTEs, however, the commission has the authority to make
exceptions when there are reasonable grounds to do so. These
grounds include the needs of patients with the disease that the
supply will target; national health programs aligned to priority
public health needs that need technology to operate and must be
addressed in a timely manner; the effect that the new supply will
have on the organization of health care services at the institu-
tions; and the potential long-term beneﬁt that the addition of the
supply may have.
The evaluation process culminates during this stage with the
deliberation and ruling that occurs during the committee meet-
ing, taking into consideration the recommendations reached
through consensus, taking 90 calendar days from the date of
submission, to give a resolution. The Technical Secretariat
prepares the supply item’s descriptive document for the appli-
cable requests, and once approved by the CTE, it is included in
the CBCISS update project that is made available for 10 calendar
days on the CSG Web site for comments from stakeholders. After
this time, the comments received are addressed and the update
is then published in the Ofﬁcial Gazette of the federation. The
update takes effect the day after its publication, and the process
is complete.Preliminary Results
To describe the experience gained, evaluate the achievements
made, and improve the process, a preliminary analysis of the
results obtained of four periods from September 2011 has been
performed.
From September 2011 to December 2012, 394 update proposals
were received over four periods (September–December 2011,
January–April, May–August, and September–December 2012). All
the requests received were reviewed and evaluated by the
commission’s Technical Secretariat within the prescribed period
of 15 days and using the criteria established in the bylaws and
the GEI.
Of the requests received, 62% were for medicines, 22% for
wound dressing materials, 8.4% for instruments and medical
equipment, and 7.1% for diagnostic aids (Fig. 1).
Within each period for receiving requests, the constant
number of requests received for medicines (mean ¼ 61) and
diagnostic aids (mean ¼ 7) stands out. In contrast, there was an
increasing trend in terms of the number of requests received for
244
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Wound dressing materials
Diagnostic aids
Instruments and medical 
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Fig. 1 – CBCISS update requests received from September 2011 to December 2012. CBCISS, Health Care Formulary and Supply
Catalog. Source: Database of the Commission’s Technical Secretariat [12].
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equipment (7–19). Furthermore, a global average of 98 requests
was determined for the four basic lists (Fig. 2).
After conﬁrming compliance with established requirements in
due time and manner, 59.9% of the requests reviewed passed on
to the next stage of the process, the evaluation, which was held
jointly by the CTEs and the Technical Secretariat. At this stage, an
increasing trend in the number of requests evaluated was noted.
For the list of medicines, the increase from the ﬁrst period to the
fourth was from 41% to 75%; for wound dressing materials, the
increase was from 30% to 76%; for diagnostic aids, it was from
25% to 50%; and for instruments and medical equipment, it was
from 42% to 81% (Fig. 3).
In the third stage, the committee approved 44.9% of the
requests evaluated over the four update periods (Fig. 4), which
corresponded to 28% for medicines, 25% for wound dressing
materials, 21% for diagnostic aids, and 27% for instruments and
medical equipment.Discussion
The strengthening of the selection process for technologies
to be included in the CBCISS was performed under a rigorous70
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Fig. 2 – CBCISS update requests received by the Technical Secre
Source: Database of the Commission’s Technical Secretariat [12methodology based on critical analysis of the scientiﬁc evidence
present in the clinical, epidemiological, and economic stu-
dies that accompanied each update proposal, applying at all
times transparency, consistency, and legitimacy backed by a
legal framework, as established by an amendment to the
commission’s bylaws. At the same time, it deﬁnes the rights
and responsibilities of the shareholders involved, as well as the
guidelines and basic principles that direct them, with the oppor-
tunity to take decisions in a reasonable time frame.
The implementation of strategies that strengthen the CBCISS
update process allows it to be thought of as an essential
regulatory tool for the introduction of health technologies, with
relevant contributions to the proper selection of cost-effective
interventions. It ensures that each supply included on the list
meets the criteria sufﬁcient and necessary to ensure efﬁcacy,
safety, effectiveness, and, of course, efﬁciency, as evidence
supporting the selection of suitable technologies.
Besides stimulating the optimization of public resources
allocated to the country’s health issues, the CBCISS, as a refer-
ence tool, offers the opportunity to have a single system of
classiﬁcation and coding of supplies at the Federal Public Admin-
istration, thus contributing to the standardization of purchasing
policies for the public institutions within the National Health
System.60 58
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GEI, in addition to the GCEEE, with strict adherence to the bylaws,
speciﬁcally Section VI “On the Procedure for Updating Supplies,”
allows for the incorporation of scientiﬁc evidence of technolog-
ical advances in medical care, ensuring its quality. It also allows
the efforts of different institutions involved in updating the
CBCISS to converge, align, and complement each other, avoiding
duplication of effort. It uses standardized criteria based on the
health needs of the Mexican population, and its use also favors
transparent processes.
With the results obtained, we note that the highest percent-
age of update requests are for medicines and that while requests
for diagnostic aids, instruments and medical equipment, and
wound dressing materials are minimal, the trend is growing,
especially for wound dressing materials.
In addition, it was noted that of the 394 total requests
received during the four periods, only 59.9% were accepted and
allowed to continue with the upgrade process, and so, the
question arises as to what were or are the possible reasons for
not meeting the explicit requirements set forth in the bylaws
and GEI.
In analyzing this very event, by observing what occurred
period by period, it seems that the trend of requests accepted19
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Fig. 4 – CBCISS update requests approved. CBCISS, Health Care
Commission’s Technical Secretariat [12].and sent to the second stage (evaluation) is on the rise, especially
for medicines and wound dressing materials.
It should be mentioned, however, that after observing the
results from the ﬁrst period (September–December 2011), after
the publication of the new bylaws as “operational policy,” the
applicant was allowed to respond to the observations of the
Technical Secretariat by resubmitting the request with the
appropriate changes, within a maximum period of 72 hours,
beginning upon receipt of the initial response. It is also important
to detail that after receiving the response (amended request), the
Technical Secretariat reviews and assesses it and then issues a
deﬁnitive answer. If a reply is not received from the applicant
within the stipulated time frame, the Technical Secretariat’s ﬁrst
response is considered ﬁnal.
With this “policy,” the increase in applications that advance to
the evaluation stage has been notable, but of these, only 44.9%
are ruled as applicable to the CBCISS update, a fact that will be
discussed in a later analysis.
There is no doubt that with the strategies developed, there
has been progress in the implementation of the project to
strengthen the update process with a regulatory framework and
rational use of HTs, promoting transparency, quality of evidence,
and efﬁciency of the national regulatory authority.21
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fundamental component of the CBCISS update process in terms
of decision making and the ruling, EE studies were taken as part
of the informational process and a support tool rather than a
decision-making method for selecting the HT, clarifying that the
main theme of the process was not “if one had to choose” but
rather “how to make the decision to choose” a proposal to be
accepted for the CBCISS update.
In conclusion, it is important to clarify that we are immersed
in a dynamic process in which weaknesses can be observed that
give us the opportunity to improve the process on a periodic basis
and/or make the necessary changes to establish a balance
between the costs and beneﬁts of HTs, where price is determined
by the value of health and the value of health is determined by
the quality of the evidence and the ability to determine adequate
health spending.
Although we do not know how much health spending is
enough to meet our endless health needs when resources are
in short supply, by setting cost-effectiveness thresholds, such as
gross domestic product per capita, a balance can be achieved
between the sectors involved and the needs of society aimed at
real population's health improvement.
These and other questions will be tackled as advances are
made in the process, the necessary adjustments are carried
out, and agreements and/or negotiations with stakeholders are
reached to address the health pressures that vex the popula-
tion and to mitigate the burden of disease with efﬁcacious,
effective, and efﬁcient technologies.
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